You are here: Home: Audio Program Guide: CCU for Surgeons 2 | 2006: Download Audio
Go to interview with Steven D Wexner, MD Go to interview with Neal J Meropol, MD Go to interview with Mark S Roh, MD Go to interview with Paulo M Hoff, MD
To listen to individual tracks, click the on the track you wish to listen to. To download tracks, right-click on the one you wish to download.

 

Steven D Wexner, MD Chief, Division of Colorectal Surgery Cleveland Clinic Florida Weston, Florida
	Click here to download the entire interview
Track 1	Introduction
Track 2	Initial evaluation of patients with rectal cancer
Track 3	Impact of neoadjuvant chemoradiation therapy on the ability to perform surgery
Track 4	Clinical use of neoadjuvant radiation with capecitabine versus continuous infusion 5-FU
Track 5	Clinical use of transanal excision
Track 6	Laparoscopic surgery for patients with colon cancer
Track 7	Morbidity associated with laparoscopic surgery for colon cancer
Track 8	Benefit of open versus laparoscopic surgery
Track 9	Laparoscopic surgery for patients with rectal cancer
Track 10	Morbidity associated with laparoscopic surgery for rectal cancer
Track 11	Randomized trial comparing laparotomy to laparoscopic surgery for rectal cancer
Track 12	Sphincter preservation
Track 13	Technical caveats to surgery for rectal cancer
Track 14	Bowel function and quality of life in patients with low rectal lesions
Track 15	New developments in surgery for colon cancer
Track 16	Virtual colonoscopy
Track 17	Adequacy of lymph node sampling
Track 18	Synchronous primary lesions and hepatic metastases
Track 19	Management of hepatic metastases
Track 20	Referral of patients with Stage II colon cancer to a medical oncologist
Track 21	Future advances in colon cancer

Neal J Meropol, MD Director, Gastrointestinal Cancer Program Director, Gastrointestinal Tumor Risk Assessment Program Divisions of Medical Science and Population Science Fox Chase Cancer Center Philadelphia, Pennsylvania
	Click here to download the entire interview
Track 1	Introduction
Track 2	Surgical resection for patients with metastatic colorectal cancer
Track 3	A 47-year-old woman with colon cancer and a synchronous solitary liver metastasis
Track 4	Tissue markers to predict response to bevacizumab
Track 5	Timing of surgery following treatment with bevacizumab
Track 6	Adjuvant therapy for patients with colon cancer
Track 7	Scheduling of FOLFOX
Track 8	Side effects and toxicities associated with FOLFOX
Track 9	Impact of FOLFOX on quality of life
Track 10	Referral of patients with Stage II or III colon cancer to a medical oncologist
Track 11	Side effects associated with capecitabine
Track 12	Advantages of oral chemotherapy

Mark S Roh, MD Chair, Department of Surgery, Allegheny General Hospital Director, Division of Surgical Oncology Professor, Human Oncology Drexel University College of Medicine Pittsburgh, Pennsylvania
	Click here to download the entire interview
Track 1	Introduction
Track 2	Trends in adjuvant therapy
Track 3	Lymph node dissection
Track 4	Laparoscopic colectomy
Track 5	Referral of patients with colon cancer to a medical oncologist
Track 6	Ongoing clinical research in the NSABP
Track 7	Follow-up for patients completing primary therapy
Track 8	Management of patients with liver-only metastases
Track 9	NSABP-C-09: CAPOX with or without intrahepatic FUDR
Track 10	Cryoablation versus radiofrequency ablation
Track 11	Problems encountered with surgery for hepatic metastases
Track 12	Quality control measures in NSABP-C-09
Track 13	Challenges associated with intrahepatic chemotherapy
Track 14	Side effects associated with intrahepatic FUDR
Track 15	Patients with synchronous primary and metastatic colon cancer
Track 16	Initial evaluation of patients with rectal cancer
Track 17	Clinical use of chemoradiation therapy in patients with rectal cancer
Track 18	Local excision and abdomino-perineal resection for rectal cancer

Paulo M Hoff, MD Executive Director Hospital Sirio Libanes São Paulo, Brazil
	Click here to download the entire interview
Track 1	Introduction
Track 2	History of adjuvant therapy for colon cancer
Track 3	Capecitabine versus 5-FU/leucovorin as adjuvant therapy
Track 4	Combination chemotherapy regimens as adjuvant therapy
Track 5	MOSAIC trial and NSABP-C-07
Track 6	Toxicities associated with oxaliplatin
Track 7	Clinical use of adjuvant chemotherapy for patients with Stage II disease
Track 8	Adequacy of lymph node sampling
Track 9	Chemotherapy selection for patients with Stage II disease
Track 10	Referral of patients with Stage II disease to a medical oncologist
Track 11	Ongoing adjuvant trials